The Experts below are selected from a list of 102 Experts worldwide ranked by ideXlab platform

L. B. A. Van De Putte - One of the best experts on this subject based on the ideXlab platform.

Jorge Garbino - One of the best experts on this subject based on the ideXlab platform.

  • anti inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis
    European Cytokine Network, 2003
    Co-Authors: Vincent L Butty, Jorge Garbino, Pascale Rouxlombard, Jeanmichel Dayer, Bara Ricou
    Abstract:

    Objectives: To investigate the effects of Lenercept ®, a recombinant soluble TNF receptor p55 fused to an immunoglobulin heavy chain IgG 1, on the balance of pro‐ and anti‐inflammatory mediators in sepsis. Design: Post hoc analysis of a subgroup of patients enrolled in a multicenter phase III, prospective, double‐blind, placebo‐controlled, randomized study of Lenercept ® in severe sepsis. Setting: Surgical and medical intensive care units, and postoperative recovery room of a tertiary care teaching hospital. Patients: A total of 57 patients were enrolled in the multicenter study in our center. Intervention: Septic patients were randomly assigned to receive either Lenercept ® 0.125 mg\kg or placebo. The patients were followed for up to 28 days after randomization. Measurements and main results: Circulating levels of TNF‐α, IL‐6, TNFsR 75 and IL‐1Ra were measured before and after treatment. The two groups were comparable with regard to age, gender and diagnosis distribution. The total level of TNF‐α increased significantly in treated patients, compared to patients receiving placebo. The levels of the other inflammatory mediators did not differ between the two groups. Conclusions: Lenercept ®‐treated patients experienced a protracted TNF‐α half‐life, leading to higher total TNF‐α levels throughout the study. However, the treatment had no effects on anti‐inflammatory mediators. Therefore, peripheral inflammatory processes might not have been significantly modified by the treatment. This might account for the lack of efficacy this treatment in septic patients.

  • Lenercept p55 tumor necrosis factor receptor fusion protein in severe sepsis and early septic shock a randomized double blind placebo controlled multicenter phase iii trial with 1 342 patients
    Critical Care Medicine, 2001
    Co-Authors: Edward Abraham, Pierrefrancois Laterre, Jorge Garbino, Susan K Pingleton, Thomas Butler, Thierry Dugernier, Benjamin Margolis, Kenneth A Kudsk, Werner Zimmerli, Paula Anderson
    Abstract:

    OBJECTIVE: Phase III study to confirm a trend observed in a previous phase II study showing that a single dose of Lenercept, human recombinant p55 tumor necrosis factor receptor-immunoglobulin G1 (TNFR55-IgG1) fusion protein, decreased mortality in patients with severe sepsis or early septic shock. DESIGN: Multicenter, double-blind, phase III, placebo-controlled, randomized study. SETTING: A total of 108 community and university-affiliated hospitals in the United States (60), Canada (6) and Europe (42). PATIENTS: A total of 1,342 patients were recruited who fulfilled the entry criteria within the 12-hr period preceding the study drug administration. INTERVENTION: After randomization, an intravenous dose of 0.125 mg/kg Lenercept or placebo was given. The patient was monitored for up to 28 days, during which standard diagnostic, supportive, and therapeutic care was provided. MEASUREMENTS AND MAIN RESULTS: The primary outcome measure was 28-day all-cause mortality. Baseline characteristics were as follows: a total of 1,342 patients were randomized; 662 received Lenercept and 680 received placebo. The mean age was 60.5 yrs (range, 17-96 yrs); 39% were female; 65% had medical admissions, 8% had scheduled surgical admissions, and 27% had unscheduled surgical admissions; 73% had severe sepsis without shock, and 27% had severe sepsis with early septic shock. Lenercept and placebo groups were similar at baseline with respect to demographic characteristics, simplified acute physiology score II-predicted mortality, profiles of clinical site of infection and microbiological documentation, number of dysfunctioning organs, and interleukin-6 (IL-6) plasma concentration. Lenercept pharmacokinetics were similar in severe sepsis and early septic shock patients. Tumor necrosis factor was bound in a stable manner to Lenercept as reflected by the accumulation of total serum tumor necrosis factor alpha concentrations. There were 369 deaths, 177 on Lenercept (27% mortality) and 192 on placebo (28% mortality). A one-sided Cochran-Armitage test, stratified by geographic region and baseline, predicted 28-day all-cause mortality (simplified acute physiology score II), gave a p value of.141 (one-sided). Lenercept treatment had no effect on incidence or resolution of organ dysfunctions. There was no evidence that Lenercept was detrimental in the overall population. CONCLUSION: Lenercept had no significant effect on mortality in the study population.

Bara Ricou - One of the best experts on this subject based on the ideXlab platform.

  • anti inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis
    European Cytokine Network, 2003
    Co-Authors: Vincent L Butty, Jorge Garbino, Pascale Rouxlombard, Jeanmichel Dayer, Bara Ricou
    Abstract:

    Objectives: To investigate the effects of Lenercept ®, a recombinant soluble TNF receptor p55 fused to an immunoglobulin heavy chain IgG 1, on the balance of pro‐ and anti‐inflammatory mediators in sepsis. Design: Post hoc analysis of a subgroup of patients enrolled in a multicenter phase III, prospective, double‐blind, placebo‐controlled, randomized study of Lenercept ® in severe sepsis. Setting: Surgical and medical intensive care units, and postoperative recovery room of a tertiary care teaching hospital. Patients: A total of 57 patients were enrolled in the multicenter study in our center. Intervention: Septic patients were randomly assigned to receive either Lenercept ® 0.125 mg\kg or placebo. The patients were followed for up to 28 days after randomization. Measurements and main results: Circulating levels of TNF‐α, IL‐6, TNFsR 75 and IL‐1Ra were measured before and after treatment. The two groups were comparable with regard to age, gender and diagnosis distribution. The total level of TNF‐α increased significantly in treated patients, compared to patients receiving placebo. The levels of the other inflammatory mediators did not differ between the two groups. Conclusions: Lenercept ®‐treated patients experienced a protracted TNF‐α half‐life, leading to higher total TNF‐α levels throughout the study. However, the treatment had no effects on anti‐inflammatory mediators. Therefore, peripheral inflammatory processes might not have been significantly modified by the treatment. This might account for the lack of efficacy this treatment in septic patients.

David Jayne - One of the best experts on this subject based on the ideXlab platform.

  • Safety and efficacy of TNFα blockade in relapsing vasculitis
    Annals of the rheumatic diseases, 2002
    Co-Authors: A D Booth, H J Jefferson, W Ayliffe, P A Andrews, David Jayne
    Abstract:

    Blockade of tumour necrosis factor alpha (TNFα) using infliximab, a chimeric monoclonal antibody against TNFα, is an effective treatment in rheumatoid arthritis and Crohn's disease.1, 2 Sifikakis reported success using infliximab in sight threatening Behcet's disease.3 A preliminary study has also reported clinical improvements in the primary systemic vasculitis, Wegener's granulomatosis, with the soluble TNFα receptor etanercept.4 The benefit of Lenercept, a soluble p55 TNFα receptor fusion protein, on digital vasculitis in rheumatoid arthritis has also …

A.a. Den Broeder - One of the best experts on this subject based on the ideXlab platform.